文献速递心脑血管急症消化、代谢与肾脏急症

2型糖尿病患者急性冠脉综合征住院后的处方取药情况

Prescription Fills Among Patients With Type 2 Diabetes After Hospitalization for Acute Coronary Syndrome.
PubMed 文献 · JAMA Netw Open · 2024-11-04
一句话结论在2型糖尿病合并急性冠脉综合征的医保受益人中,出院时未取药与出院后90–180天未取该药相关(如β受体阻滞剂调整风险比0.24)。

这项回顾性队列研究利用美国医疗保险和医疗补助服务中心2018年1月1日至2020年6月30日数据,纳入188 651例因心肌梗死或冠状动脉血运重建住院的2型糖尿病医保受益人,中位年龄73.0岁,男性111 982例(59.4%)。研究考察出院前90天、出院时(≤90天)及出院后91–180天五类心血管药物(ACEI/ARB/ARNI、β受体阻滞剂、P2Y12抑制剂、他汀/PCSK9抑制剂、SGLT2抑制剂/GLP-1受体激动剂)的处方取药记录。Logistic回归显示,出院后未取某类心血管药物与出院时未取该药相关:ACEI/ARB/ARNI调整风险比0.27(95%CI 0.27–0.28),β受体阻滞剂0.24(0.24–0.25),P2Y12抑制剂0.20(0.19–0.20),他汀/PCSK9抑制剂0.31(0.31–0.32),SGLT2抑制剂/GLP-1受体激动剂0.27(0.26–0.28)。作者认为住院至出院过渡期对优化这些高危患者的预防性治疗至关重要,并需进一步实施科学研究以改善循证药物使用。

要点

  • 在188 651例2型糖尿病合并急性冠脉综合征的医保受益人中,出院时未取药与出院后91–180天未取该药相关:β受体阻滞剂调整风险比0.24(95%CI 0.24–0.25)。
  • P2Y12抑制剂出院时未取药与出院后未取药的调整风险比0.20(95%CI 0.19–0.20),为五类药物中关联最强。
  • 他汀/PCSK9抑制剂出院时未取药与出院后未取药的调整风险比0.31(95%CI 0.31–0.32),关联相对最弱。
  • ACEI/ARB/ARNI与SGLT2抑制剂/GLP-1受体激动剂的对应调整风险比分别为0.27(95%CI 0.27–0.28)和0.27(95%CI 0.26–0.28)。
  • 作者认为住院至出院过渡期对优化2型糖尿病合并急性冠脉综合征高危患者的预防性治疗至关重要。

适用人群与场景

  • 纳入:年龄大于18岁、有2型糖尿病、因心肌梗死或冠状动脉血运重建住院、在2018年1月1日至2020年6月30日期间有符合条件住院的Medicare受益人。
  • 场景:住院前90天、出院时(≤90天)及出院后91–180天的处方取药过渡期。

研究设计与关键结果

  • 研究类型:回顾性队列研究,使用美国医疗保险和医疗补助服务中心2018年1月1日至2020年6月30日数据,纳入188 651例2型糖尿病合并急性冠脉综合征的Medicare受益人;中位年龄73.0岁(IQR 67.0–79.0),男性111 982例(59.4%),黑人18 383例(9.7%),白人153 461例(81.3%)。
  • 主要终点:出院后未取某类心血管药物与出院时未取该药相关,ACEI/ARB/ARNI调整风险比0.27(95%CI 0.27–0.28),β受体阻滞剂0.24(0.24–0.25),P2Y12抑制剂0.20(0.19–0.20),他汀/PCSK9抑制剂0.31(0.31–0.32),SGLT2抑制剂/GLP-1受体激动剂0.27(0.26–0.28)。
  • 数据分析于2023年6月进行。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些发现突出表明住院至出院过渡期对优化2型糖尿病合并急性冠脉综合征高危患者预防性治疗至关重要。
  • 作者认为需要进一步实施科学研究以制定策略改善这些循证药物的使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Individuals with type 2 diabetes (T2D) have high rates of mortality following myocardial infarction (MI). Hospitalization is an opportunity to initiate or continue evidence-based treatment to reduce risk in individuals with T2D and acute coronary syndrome (ACS).

OBJECTIVE: To determine patterns of evidence-based medication use during the period of transition from admission to discharge after hospitalization for MI or coronary revascularization among individuals with T2D and ACS.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the Centers for Medicare & Medicaid Services (CMS) for January 1, 2018, to June 30, 2020. Medicare beneficiaries older than 18 years with T2D with a qualifying hospitalization were included. Individuals were followed before admission (90 days prior), at discharge (≤90 days), and after discharge (91-180 days after) from a hospitalization for MI or coronary revascularization. Data analysis was performed in June 2023.

EXPOSURES: Demographic data (race, sex, rural vs urban location of care, and comorbidities) were abstracted from CMS data using Master Beneficiary and Summary Files and International Statistical Classification of Diseases, Tenth Revision codes.

MAIN OUTCOME AND MEASURES: Medicare Part D prescription fill records were examined for the following agents: (1) angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); (2) β-blockers; (3) platelet adenosine diphosphate receptor inhibitors (P2Y12Is); (4) statins or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is); and (5) glucagon-like peptide 1 receptor agonists (GLP-1RAs) or sodium glucose cotransporter 2 inhibitors (SGLT2Is). Logistic regression analysis was used to examine the association between covariates and lack of prescription fills in the postdischarge period.

RESULTS: A total of 188 651 eligible Medicare beneficiaries with T2D and hospitalization for MI or coronary revascularization were identified. Their median age was 73.0 (IQR, 67.0-79.0) years, and more than half (111 982 [59.4%]) were men; 18 383 (9.7%) were Black and 153 461 (81.3%) were White. Not filling a cardiovascular medication after hospitalization was associated with not filling that medication at the time of discharge (adjusted risk ratio, 0.27 [95% CI, 0.27-0.28] for ACEIs, ARBs, or ARNIs; 0.24 [0.24-0.25] for β-blockers; 0.20 [0.19-0.20] for P2Y12Is; 0.31 [0.31-0.32] for statins or PCSK9Is; and 0.27 [0.26-0.28] for SGLT2Is or GLP-1RAs).

CONCLUSIONS AND RELEVANCE: In this cohort study of Medicare beneficiaries with T2D, longer-term medication use following hospitalization for MI was associated with medication use at the time of discharge. These findings highlight the critical importance of this period to optimize preventive care for these high-risk individuals. Further implementation science research is needed to develop strategies to improve use of these evidence-based medications.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Kelsey MD, Ford C, Oakes M, et al. Prescription Fills Among Patients With Type 2 Diabetes After Hospitalization for Acute Coronary Syndrome. JAMA Netw Open. 2024. PMID: 39602121. doi:10.1001/jamanetworkopen.2024.47102

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。